Carisma Current Deferred Revenue vs Total Current Liabilities Analysis

CARM Stock

0.56 0.13 18.84%

Carisma Therapeutics financial indicator trend analysis is way more than just evaluating Carisma Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Carisma Therapeutics is a good investment. Please check the relationship between Carisma Therapeutics Current Deferred Revenue and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.

Current Deferred Revenue vs Total Current Liabilities

Current Deferred Revenue vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Carisma Therapeutics Current Deferred Revenue account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Carisma Therapeutics' Current Deferred Revenue and Total Current Liabilities is 0.53. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Carisma Therapeutics, assuming nothing else is changed. The correlation between historical values of Carisma Therapeutics' Current Deferred Revenue and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Carisma Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Current Deferred Revenue i.e., Carisma Therapeutics' Current Deferred Revenue and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Total Current Liabilities

Total Current Liabilities is an item on Carisma Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Carisma Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Carisma Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Carisma Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.As of the 11th of December 2024, Selling General Administrative is likely to grow to about 31 M, while Issuance Of Capital Stock is likely to drop about 24 M.

	2021	2022	2023	2024 (projected)
Interest Expense	8.3M	3.1M	1.9M	2.0M
Depreciation And Amortization	85K	6.1M	2.8M	3.0M

Interest Expense Depreciation And Amortization

Carisma Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Good Will	Intangible Assets	Other Assets	Net Tangible Assets
Total Assets		0.12	0.56	0.43	0.18	0.13	-0.58	-0.82	0.31	0.61	0.78	0.1	0.64	0.26	0.83	0.61	0.75	0.83	0.65	0.3	0.11	0.26	-0.58	-0.34	0.02	-0.12
Short Long Term Debt Total	0.12		0.65	0.71	-0.57	0.56	0.38	-0.12	-0.03	-0.02	-0.09	0.18	0.24	-0.2	0.29	0.15	-0.19	0.35	0.24	-0.25	0.34	0.66	-0.08	-0.31	-0.09	-0.41
Other Current Liab	0.56	0.65		0.91	-0.53	0.68	-0.1	-0.68	0.27	0.35	0.24	0.1	0.54	0.28	0.71	0.68	0.3	0.77	0.56	0.15	0.69	0.62	-0.67	-0.74	-0.2	-0.67
Total Current Liabilities	0.43	0.71	0.91		-0.41	0.8	-0.17	-0.59	0.49	0.46	-0.02	0.04	0.65	0.41	0.49	0.53	0.24	0.57	0.66	0.08	0.53	0.83	-0.59	-0.76	-0.07	-0.73
Total Stockholder Equity	0.18	-0.57	-0.53	-0.41		-0.31	-0.59	0.06	0.27	0.41	0.11	-0.19	0.22	0.26	-0.35	-0.45	0.34	-0.37	0.19	0.18	-0.5	-0.24	0.0	0.17	0.25	0.26
Property Plant And Equipment Net	0.13	0.56	0.68	0.8	-0.31		-0.13	-0.3	0.49	0.4	-0.28	-0.18	0.58	0.58	0.15	0.28	0.0	0.24	0.58	0.13	0.61	0.69	-0.63	-0.87	0.12	-0.89
Net Debt	-0.58	0.38	-0.1	-0.17	-0.59	-0.13		0.64	-0.67	-0.93	-0.14	0.15	-0.8	-0.74	-0.24	-0.38	-0.77	-0.25	-0.79	-0.45	0.12	-0.15	0.59	0.38	-0.21	0.17
Retained Earnings	-0.82	-0.12	-0.68	-0.59	0.06	-0.3	0.64		-0.32	-0.72	-0.49	-0.23	-0.74	-0.57	-0.82	-0.77	-0.87	-0.84	-0.76	-0.25	-0.2	-0.49	0.72	0.56	0.23	0.37
Accounts Payable	0.31	-0.03	0.27	0.49	0.27	0.49	-0.67	-0.32		0.72	-0.22	-0.44	0.7	0.62	0.03	0.35	0.23	0.08	0.69	0.44	0.18	0.28	-0.49	-0.52	0.46	-0.42
Cash	0.61	-0.02	0.35	0.46	0.41	0.4	-0.93	-0.72	0.72		0.05	-0.1	0.96	0.76	0.33	0.44	0.74	0.36	0.96	0.37	0.01	0.43	-0.68	-0.56	0.19	-0.39
Non Current Assets Total	0.78	-0.09	0.24	-0.02	0.11	-0.28	-0.14	-0.49	-0.22	0.05		0.22	0.04	-0.16	0.73	0.33	0.51	0.68	0.05	0.12	-0.01	-0.14	-0.21	0.07	-0.15	0.23
Non Currrent Assets Other	0.1	0.18	0.1	0.04	-0.19	-0.18	0.15	-0.23	-0.44	-0.1	0.22		-0.06	-0.04	0.34	0.02	0.37	0.32	-0.05	-0.85	-0.45	0.16	0.27	0.28	-0.65	0.25
Cash And Short Term Investments	0.64	0.24	0.54	0.65	0.22	0.58	-0.8	-0.74	0.7	0.96	0.04	-0.06		0.72	0.42	0.5	0.66	0.47	1.0	0.31	0.15	0.58	-0.72	-0.66	0.17	-0.52
Common Stock Shares Outstanding	0.26	-0.2	0.28	0.41	0.26	0.58	-0.74	-0.57	0.62	0.76	-0.16	-0.04	0.72		0.1	0.28	0.58	0.14	0.71	0.22	0.13	0.44	-0.68	-0.72	-0.01	-0.61
Non Current Liabilities Total	0.83	0.29	0.71	0.49	-0.35	0.15	-0.24	-0.82	0.03	0.33	0.73	0.34	0.42	0.1		0.81	0.62	0.99	0.45	0.1	0.24	0.28	-0.48	-0.29	-0.22	-0.13
Other Current Assets	0.61	0.15	0.68	0.53	-0.45	0.28	-0.38	-0.77	0.35	0.44	0.33	0.02	0.5	0.28	0.81		0.47	0.82	0.54	0.37	0.4	0.26	-0.56	-0.43	-0.01	-0.27
Other Stockholder Equity	0.75	-0.19	0.3	0.24	0.34	0.0	-0.77	-0.87	0.23	0.74	0.51	0.37	0.66	0.58	0.62	0.47		0.61	0.67	0.08	-0.22	0.29	-0.51	-0.28	-0.27	-0.08
Total Liab	0.83	0.35	0.77	0.57	-0.37	0.24	-0.25	-0.84	0.08	0.36	0.68	0.32	0.47	0.14	0.99	0.82	0.61		0.5	0.1	0.29	0.36	-0.52	-0.36	-0.22	-0.21
Total Current Assets	0.65	0.24	0.56	0.66	0.19	0.58	-0.79	-0.76	0.69	0.96	0.05	-0.05	1.0	0.71	0.45	0.54	0.67	0.5		0.32	0.17	0.58	-0.73	-0.67	0.16	-0.52
Common Stock	0.3	-0.25	0.15	0.08	0.18	0.13	-0.45	-0.25	0.44	0.37	0.12	-0.85	0.31	0.22	0.1	0.37	0.08	0.1	0.32		0.51	-0.11	-0.55	-0.43	0.43	-0.3
Current Deferred Revenue	0.11	0.34	0.69	0.53	-0.5	0.61	0.12	-0.2	0.18	0.01	-0.01	-0.45	0.15	0.13	0.24	0.4	-0.22	0.29	0.17	0.51		0.2	-0.64	-0.71	0.1	-0.67
Short Term Debt	0.26	0.66	0.62	0.83	-0.24	0.69	-0.15	-0.49	0.28	0.43	-0.14	0.16	0.58	0.44	0.28	0.26	0.29	0.36	0.58	-0.11	0.2		-0.41	-0.6	-0.11	-0.61
Good Will	-0.58	-0.08	-0.67	-0.59	0.0	-0.63	0.59	0.72	-0.49	-0.68	-0.21	0.27	-0.72	-0.68	-0.48	-0.56	-0.51	-0.52	-0.73	-0.55	-0.64	-0.41		0.85	-0.19	0.64
Intangible Assets	-0.34	-0.31	-0.74	-0.76	0.17	-0.87	0.38	0.56	-0.52	-0.56	0.07	0.28	-0.66	-0.72	-0.29	-0.43	-0.28	-0.36	-0.67	-0.43	-0.71	-0.6	0.85		0.03	0.94
Other Assets	0.02	-0.09	-0.2	-0.07	0.25	0.12	-0.21	0.23	0.46	0.19	-0.15	-0.65	0.17	-0.01	-0.22	-0.01	-0.27	-0.22	0.16	0.43	0.1	-0.11	-0.19	0.03		0.16
Net Tangible Assets	-0.12	-0.41	-0.67	-0.73	0.26	-0.89	0.17	0.37	-0.42	-0.39	0.23	0.25	-0.52	-0.61	-0.13	-0.27	-0.08	-0.21	-0.52	-0.3	-0.67	-0.61	0.64	0.94	0.16

Click cells to compare fundamentals

Carisma Therapeutics Account Relationship Matchups

Carisma Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	114.4M	58.5M	35.4M	72.2M	89.6M	65.7M
Other Current Liab	6.6M	1.6M	4.5M	10.9M	6.7M	4.1M
Total Current Liabilities	8.5M	5.7M	7.7M	19.7M	15.9M	8.0M
Total Stockholder Equity	(26.7M)	35.8M	11.6M	(49.3M)	26.5M	27.9M
Property Plant And Equipment Net	238K	5.2M	5.7M	13.5M	8.9M	9.4M
Net Debt	(48.1M)	(48.3M)	(25.9M)	16.0M	(74.5M)	(70.8M)
Retained Earnings	(293.5M)	(56.2M)	(97.0M)	(158.2M)	(245.1M)	(232.8M)
Accounts Payable	1.9M	3.3M	2.3M	1.7M	3.9M	2.1M
Cash	48.1M	51.8M	28.6M	24.2M	77.6M	81.5M
Non Current Assets Total	59.9M	5.4M	5.7M	17.6M	9.1M	8.6M
Non Currrent Assets Other	196K	(78.5M)	(84.9M)	4.1M	146K	153.3K
Cash And Short Term Investments	48.1M	51.8M	28.6M	52.0M	77.6M	81.5M
Common Stock Shares Outstanding	4.5M	5.9M	9.1M	106.4K	33.5M	35.2M
Liabilities And Stockholders Equity	114.4M	58.5M	35.4M	72.2M	89.6M	65.7M
Non Current Liabilities Total	132.5M	2.6M	1.7M	81.6M	47.1M	39.8M
Other Current Assets	6.3M	1.3M	1.2M	2.6M	2.9M	1.5M
Other Stockholder Equity	266.8M	199K	619K	1.2M	271.6M	285.2M
Total Liab	141.1M	8.3M	9.4M	101.3M	63.0M	47.8M
Total Current Assets	54.4M	53.1M	29.8M	54.6M	80.5M	84.5M
Accumulated Other Comprehensive Income	(758K)	(140K)	(199K)	(41K)	(89.6M)	(85.1M)
Common Stock	77K	107K	140K	199K	40K	56.4K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Carisma Therapeutics is a strong investment it is important to analyze Carisma Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Carisma Therapeutics' future performance. For an informed investment choice regarding Carisma Stock, refer to the following important reports:

How To Invest In Carisma

Details

Is Carisma Stock a good investment?

Details

What is Carisma Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.52)

Revenue Per Share

0.493

Quarterly Revenue Growth

(0.12)

Return On Assets

(0.56)

Return On Equity

(3.63)

The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Carisma Current Deferred Revenue vs Total Current Liabilities Analysis

Current Deferred Revenue vs Total Current Liabilities

Current Deferred Revenue vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Total Current Liabilities

Carisma Therapeutics fundamental ratios Correlations

Carisma Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Carisma Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Cash
Total Current Assets	+ 0.96	Cash
Net Tangible Assets	+ 0.94	Intangible Assets
Total Current Liabilities	+ 0.91	Other Current Liab

Cash	- 0.93	Net Debt
Net Tangible Assets	- 0.89	Property Plant And Equipment Net
Other Stockholder Equity	- 0.87	Retained Earnings
Intangible Assets	- 0.87	Property Plant And Equipment Net
Common Stock	- 0.85	Non Currrent Assets Other
Total Liab	- 0.84	Retained Earnings